{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T05:21:38Z","timestamp":1735708898399,"version":"3.32.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>The recent trial Pediatric Neuro-Oncology Consortium 003 (PNOC003) utilized a molecular tumor board to recommend personalized treatment regimens based on tumor sequencing results in children with DIPG. We separately developed the Central Nervous System Targeted Agent Prediction (CNS-TAP) tool, which numerically scores targeted anticancer agents using preclinical, clinical, and patient-specific data. We hypothesized that highly scored agents from CNS-TAP would overlap with the PNOC003 tumor board\u2019s recommendations. For each of the 28 participants, actionable genetic alterations were derived from PNOC003 genomic reports and input to CNS-TAP to identify the highest scoring agents. These agents were then compared with PNOC003 recommendations, with a resultant concordance percentage calculated. Overall, 38% of the total agents recommended by the tumor board were also selected by CNS-TAP, with higher concordance (63%) in a subanalysis including only targeted anticancer agents. Furthermore, nearly all patients (93%) had at least 1 drug chosen by both methods. We demonstrate overlap between agents recommended by CNS-TAP and PNOC003 tumor board, though this does not appear to improve survival. We do observe some discordance, highlighting strengths and limitations of each method. We propose that a combination of expert opinion and data-driven tools may improve targeted treatment recommendations for children with DIPG.<\/jats:p>","DOI":"10.1097\/mph.0000000000002964","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:10Z","timestamp":1731369610000},"page":"19-30","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Comparison of Targeted Anticancer Drugs Predicted by the CNS-TAP Tool Versus Those Selected by a Molecularly Driven Tumor Board in Children With DIPG"],"prefix":"10.1097","volume":"47","author":[{"given":"Holly J.","family":"Roberts","sequence":"first","affiliation":[{"name":"Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ravi","sequence":"additional","affiliation":[{"name":"Stanford Medicine, Palo Alto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard L.","family":"Marini","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Services, University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Schepers","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Services, University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassie","family":"Kline","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Kilburn","sequence":"additional","affiliation":[{"name":"Children\u2019s National Health System, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-2075","authenticated-orcid":false,"given":"Michael","family":"Prados","sequence":"additional","affiliation":[{"name":"Neurosurgery and Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"Byron","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Sturza","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[{"name":"Neurology, Neurosurgery, and Pediatrics, San Francisco School of Medicine, University of California, San Francisco, CA"},{"name":"Department of Pediatrics, University of Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Koschmann","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-7683","authenticated-orcid":false,"given":"Andrea T.","family":"Franson","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"R2-20241231","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ncl.2018.04.009","article-title":"Pediatric brain tumors","volume":"36","author":"Udaka","year":"2018","journal-title":"Neurol Clin"},{"key":"R3-20241231","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2009.26.7252","article-title":"Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease","volume":"28","author":"Paugh","year":"2010","journal-title":"J Clin Oncol"},{"key":"R4-20241231","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11910-013-0346-3","article-title":"Brainstem glioma: a review","volume":"13","author":"Grimm","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R5-20241231","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","article-title":"Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study","volume":"19","author":"Cooney","year":"2017","journal-title":"Neuro Oncol"},{"key":"R6-20241231","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"R7-20241231","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","article-title":"Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol"},{"key":"R8-20241231","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CCO.0000000000000577","article-title":"Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets","volume":"31","author":"Aziz-Bose","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"R9-20241231","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1158\/1078-0432.CCR-14-0833","article-title":"Molecular insights into pediatric brain tumors have the potential to transform therapy","volume":"20","author":"Gajjar","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R10-20241231","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1002\/wdev.342","article-title":"Developmental origins and oncogenic pathways in malignant brain tumors","volume":"8","author":"Lu","year":"2019","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"R11-20241231","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11912-020-00912-z","article-title":"Targeting and therapeutic monitoring of H3K27M-mutant glioma","volume":"22","author":"Wierzbicki","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"R12-20241231","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.currproblcancer.2017.01.002","article-title":"Pediatric oncology enters an era of precision medicine","volume":"41","author":"Seibel","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"R13-20241231","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/ijc.32258","article-title":"A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: a report from the Pacific Pediatric Neuro-Oncology Consortium","volume":"145","author":"Mueller","year":"2019","journal-title":"Int J Cancer"},{"key":"R14-20241231","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-017-2708-1","article-title":"Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology","volume":"137","author":"Linzey","year":"2018","journal-title":"J Neurooncol"},{"key":"R15-20241231","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"R16-20241231","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJMc2101264","article-title":"Lorlatinib in a child with ALK-fusion-positive high-grade glioma","volume":"385","author":"Bagchi","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-20241231","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/neuonc\/noac096","article-title":"Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma","volume":"24","author":"Rosenberg","year":"2022","journal-title":"Neuro Oncol"},{"key":"R18-20241231","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/neuonc\/nor077","article-title":"Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme","volume":"13","author":"Bai","year":"2011","journal-title":"Neuro Oncol"},{"key":"R19-20241231","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/neuonc\/nou234","article-title":"Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis","volume":"17","author":"Bai","year":"2015","journal-title":"Neuro Oncol"},{"key":"R20-20241231","first-page":"vdaa154","article-title":"Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial","volume":"3","author":"Gallia","year":"2020","journal-title":"Neurooncol Adv"},{"key":"R21-20241231","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-12-0334","article-title":"Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency","volume":"72","author":"See","year":"2012","journal-title":"Cancer Res"},{"key":"R22-20241231","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-20241231","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noae064.316","article-title":"HGG-32. PNOC008: a pilot trial testing the clinical benefit of using molecular profiling to determine an individualized treatment plan in children and young adults with newly diagnosed high-grade glioma (excluding diffuse intrinsic pontine glioma)","volume":"26","author":"Franson","year":"2024","journal-title":"Neuro Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:27:20Z","timestamp":1735658840000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002964","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"type":"print","value":"1077-4114"},{"type":"electronic","value":"1536-3678"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"2024-06-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}